Autism Spectrum Disorders Clinical Trial
Official title:
Extracellular Signal-Related Kinase Biomarker Development in Autism
The purpose of this research study is to establish a way to help the development of targeted treatments in autism spectrum disorders. This may also help in early diagnosis of autism and may possibly predict severity. The study will compare subject's ERK (extracellular signal-related kinase) signaling to age- and gender-matched neurotypical controls and Intelligence quotient (IQ)-matched developmental disabilities.
Autism Spectrum Disorder Subject Criteria:
Inclusion Criteria:
- Diagnosis of autism spectrum disorder, based upon a clinical interview utilizing the
Diagnostic and Statistical Manual-V (DSM-V)
- Age 3-25 years
- Stable dosing of psychotropic drugs for greater than or equal to 5 half-lives
Exclusion Criteria:
- Diagnosis of schizophrenia, another psychotic disorder, bipolar disorder, or alcohol or
other substance abuse based on Diagnostic and Statistical Manual-V criteria
- Use of lithium, riluzole or other known modulators of ERK activation
Age-Matched Neurotypical Control Subjects:
- Age matched to the age of an Autistic Disorder Subject
- History of normal development
IQ-Matched Control Subjects:
- Those subjects who are included in the study based on having an IQ and age that matches
the IQ and age of an Autistic Disorder Subject who has an IQ less than 70
- All IQ-Matched Control Subjects will then also have an IQ less than 70
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT02625116 -
ELENA Cohort: A Long-term Longitudinal Study in a Pediatric Sample With Autism Spectrum Disorders
|
||
| Not yet recruiting |
NCT06381856 -
Improving Participation of Autistic Children and Adolescents in the Habilitation Process
|
||
| Recruiting |
NCT02280746 -
Gluten for Autism Spectrum Disorders
|
N/A | |
| Completed |
NCT01945957 -
Brain Imaging of Intranasal Oxytocin Treatment in Autism
|
Phase 1 | |
| Completed |
NCT01661855 -
A Pilot Study of Riluzole Versus Placebo in the Treatment of Children and Adolescents With ASD
|
Phase 2 | |
| Completed |
NCT01592747 -
Withdrawal Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified Previously Treated With Memantine
|
Phase 2 | |
| Completed |
NCT01780090 -
Handheld Technology for Speech Development in Students With Autism
|
N/A | |
| Completed |
NCT01691066 -
Pivotal Response Treatment for Infants At-Risk for Autism Spectrum Disorder
|
N/A | |
| Completed |
NCT01694667 -
Omega-3 Fatty Acids for Hyperactivity Treatment in Autism Spectrum Disorder
|
Phase 2 | |
| Active, not recruiting |
NCT01417026 -
Intranasal Oxytocin and Learning in Autism
|
Phase 2 | |
| Enrolling by invitation |
NCT01364818 -
Brain Connectivity in Neurodevelopmental Disorders in Response to Treatment
|
N/A | |
| Completed |
NCT01695200 -
Omega-3 Fatty Acids in Autism Spectrum Disorders
|
Phase 4 | |
| Completed |
NCT02300597 -
Internet-based Support for Young People With ADHD and Autism - a Controlled Study
|
N/A | |
| Not yet recruiting |
NCT00695812 -
The Development of Younger Siblings of Children With Autism Now at 10 Years of Age
|
N/A | |
| Completed |
NCT01675414 -
Understanding Gastrointestinal Conditions in Children With Autism Spectrum Disorder (ASD)
|
N/A | |
| Recruiting |
NCT05910502 -
Project AFECT (Autism Family Empowerment Coaching and Training Program)
|
N/A | |
| Completed |
NCT02081027 -
Pilot Study of Riluzole for Drug-Refractory Irritability in Autism Spectrum Disorders
|
Early Phase 1 | |
| Completed |
NCT02797379 -
The Development of a Psychoeducational Tool to Manage Anxiety in People With Autism Spectrum Disorders
|
N/A | |
| Terminated |
NCT01730079 -
Near Infrared Spectroscopy in Children With Autism and ADHD
|
||
| Completed |
NCT01603225 -
Transcranial Direct Current Stimulation and Autism
|